Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models

The effectual clinical benefits of immune checkpoint inhibitor (ICI) are hampered by a high rate of innate resistance, and VEGFA may contribute to ICI treatment resistance. In this study, we endeavored to assess the tumor microenvironment (TME) in VEGFA-overexpressed human tumors and mouse tumor mod...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer Immunology, Immunotherapy Immunotherapy, 2020-09, Vol.69 (9), p.1781-1799
Hauptverfasser:	Wang, Qiaohong, Gao, Jingze, Di, Wen, Wu, Xia
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis Animal models Animals B7-H1 Antigen - metabolism Breast Cancer Research Cell Line, Tumor Colon Disease Models, Animal Female Flow cytometry Humans Hypoxia Immune checkpoint inhibitors Immunity, Innate - drug effects Immunity, Innate - immunology Immunofluorescence Immunohistochemistry Immunohistochemistry - methods Immunology Immunostimulation Immunotherapy - methods Malignancy Medicine Medicine & Public Health Mice Mice, Inbred BALB C Monoclonal antibodies mRNA Neoplasms - immunology Neoplasms - metabolism Neoplasms - therapy Neovascularization, Pathologic - drug therapy Neovascularization, Pathologic - immunology Neovascularization, Pathologic - metabolism Oncology Original Original Article PD-1 protein PD-L1 protein Prognosis Programmed Cell Death 1 Receptor - metabolism Pyridines - pharmacology Treatment resistance Tumor cells Tumor Microenvironment - drug effects Tumor Microenvironment - immunology Tumors Vascular Endothelial Growth Factor A - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!